Ce jeudi 13 décembre, le Gouvernement wallon, sur proposition du Ministre de la Recherche et de l’Innovation, a annoncé officiellement la signature de la convention relative au partenariat d’innovation technologique (PIT) « Prother-wal », projet à la base du financement du futur centre de protonthérapie à Charleroi. Découvrez le communiqué de presse ici.Read more
Aquilon Pharmaceuticals S.A., spin-off of Liege University, established in 2013 and expert in the treatment of serious lung diseases has raised € 6.6 million for its clinical (Phase I/IIa) and commercial development.
"Completing phase I/IIa of the clinical studies confirming our expertise and negotiating future distribution licences were the two major objectives pursued; the fundraising campaign which closed on 30 November 2018 will allow us to achieve them. This fundraising is balanced and involves both private and public partners. It provides us with the necessary resources for Aquilon Pharma's development, both clinical and commercial, notably on the Canadian and US markets," said Paul Maes, the CEO of Aquilon Pharma.
"We worked in Aquilon alongside our partners BeAngels and SCALE1 and in addition to Spinventure, given the interest of the project and the possible collaborations with the biotech ecosystem of the Gosselies Biopark. Thanks to the funds raised, the company will be able to accelerate its development and we are happy to be able to help them with their project," said Anne Prignon, CEO of Sambrinvest.
Discover the official press release here.